Get the Stockscreener App
19.79
3.18%
0.61
After Hours:
19.52
-0.27
-1.36%
Sarepta Therapeutics Inc stock is traded at $19.79, with a volume of 2.43M.
It is up +3.18% in the last 24 hours and up +25.65% over the past month.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
See More
Previous Close:
$19.18
Open:
$19.27
24h Volume:
2.43M
Relative Volume:
0.78
Market Cap:
$2.09B
Revenue:
$2.18B
Net Income/Loss:
$-64.32M
P/E Ratio:
-20.53
EPS:
-0.9641
Net Cash Flow:
$91.18M
1W Performance:
+10.13%
1M Performance:
+25.65%
6M Performance:
-15.64%
1Y Performance:
+14.26%
1-Day Range:
$18.63
$19.85
1-Week Range:
$17.45
$19.85
52-Week Range:
$10.41
$25.32
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
19.79 | 2.02B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. – LSE:0L35 - TradingView
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® - Sarepta Therapeutics
Sarepta Refused FDA’s Request to Halt Elevidys Shipments - MSN
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Trading Systems Reacting to (SRPT) Volatility - Stock Traders Daily
SRPTSarepta Therapeutics Inc Volatility & Greeks - Finviz
ETFs Investing in Sarepta Therapeutics, Inc. Stocks - TradingView
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Sarepta Therapeutics Jumps 6.5% Amid Sector-Wide Rally - AlphaStreet
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs - Sahm
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail - BioSpace
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5 - Moomoo
SRPT Stock Quote Price and Forecast - CNN
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in Duchenne - BioPharm International
FDA Accepts Sarepta's Applications for Full Approval of Two DMD Treatments - Intellectia AI
SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies - Stocktwits
Mizuho reiterates Sarepta stock rating after FDA filing acceptance By Investing.com - Investing.com Canada
Why is Sarepta Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Sarepta stock jumps as FDA accepts DMD drug applications - Investing.com UK
Sarepta stock jumps as FDA accepts DMD drug applications By Investing.com - Investing.com Nigeria
Sarepta (SRPT) Seeks Traditional Approval for Duchenne Therapies - GuruFocus
FDA accepts Sarepta filings for two Duchenne therapies - Investing.com
FDA accepts Sarepta filings for two Duchenne therapies By Investing.com - Investing.com Canada
FDA to review Sarepta’s Duchenne drugs, with decision due Feb. 28, 2027 - Stock Titan
Sarepta Therapeutics (SRPT) Following FDA Filings And The Case For A Reset Valuation - Sahm
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Value Benchmark - marketscreener.com
Sarepta Therapeutics (SRPT) Stock Analysis: Unveiling a 30% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Dynamic Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Value Benchmark - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutic - The National Law Review
Investors SueWallSt as Sarepta Therapeutics, Inc. Faces Securities Fraud Allegations - The National Law Review
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Did You Lose Money on Sarepta Therapeutics, Inc. (SRPT)? Levi & K - The National Law Review
Class Action Lawsuit Filed: Sarepta Therapeutics, Inc. (SRPT) – Join by August 25, 2025Contact Levi & Korsinsky - The National Law Review
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - The National Law Review
Class Action Lawsuit Filed Against Sarepta Therapeutics, Inc. (SR - The National Law Review
Sarepta Therapeutics Rises As Gene Therapy Outlook Strengthens - StocksToTrade
SRPT Rises As Sarepta Gains Gene Therapy Momentum - timothysykes.com
SRPT Jumps As Sarepta Wins Tailwinds In Gene Therapy - StocksToTrade
Sarepta Therapeutics Stock Firms As Gene Therapy Tailwinds Build - timothysykes.com
Sarepta Therapeutics, Inc. Actuals & Estimates (BMV:SRPT) - TradingView
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):